Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

102.17
-2.1400-2.05%
Pre-market: 104.001.83+1.79%08:00 EDT
Volume:1.05M
Turnover:108.20M
Market Cap:6.52B
PE:-49.84
High:105.69
Open:103.25
Low:102.01
Close:104.31
52wk High:105.69
52wk Low:39.60
Shares:63.81M
Float Shares:43.15M
Volume Ratio:0.79
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0500
EPS(LYR):-2.0500
ROE:-20.18%
ROA:-13.99%
PB:10.61
PE(LYR):-49.84

Loading ...

Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide

Simply Wall St.
·
Dec 15, 2025

Protagonist Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
Dec 09, 2025

Takeda and Protagonist Report Phase 3 Study Shows Rusfertide Sustains Hematocrit Control in Polycythemia Vera

Reuters
·
Dec 08, 2025

Takeda Reports 52-Week Phase 3 Data Showing Rusfertide Maintains Hematocrit Control in Polycythemia Vera

Reuters
·
Dec 06, 2025

J.P. Morgan Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)

TIPRANKS
·
Nov 21, 2025

U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe's

Reuters
·
Nov 20, 2025

Top Executive Sells Thousands in Protagonist Therapeutics Stock!

TIPRANKS
·
Nov 20, 2025

Protagonist Therapeutics Q3 EPS USD -0.62

Reuters
·
Nov 20, 2025

H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)

TIPRANKS
·
Nov 15, 2025

Protagonist Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
Nov 11, 2025

Stock Track | Protagonist Therapeutics Soars 5.11% Following Analyst Price Target Hikes

Stock Track
·
Nov 11, 2025

Stock Track | Protagonist Therapeutics Soars 5.11% Following Analyst Price Target Increases

Stock Track
·
Nov 11, 2025

Protagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs

TIPRANKS
·
Nov 10, 2025

Protagonist Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 08, 2025

Protagonist Therapeutics Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 07, 2025

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
Nov 07, 2025

Protagonist Therapeutics price target raised to $91 from $74 at Clear Street

TIPRANKS
·
Nov 07, 2025

Protagonist Therapeutics Advances Pipeline Amid Financial Loss

TIPRANKS
·
Nov 07, 2025

The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Upcoming Rusfertide Phase 3 Data Presentation

Simply Wall St.
·
Nov 07, 2025

Protagonist Therapeutics Q3 net loss widens to $39.3 mln

Reuters
·
Nov 07, 2025